<HashMap><database>biostudies-literature</database><scores><citationCount>0</citationCount><reanalysisCount>0</reanalysisCount><viewCount>58</viewCount><searchCount>0</searchCount></scores><additional><submitter>Skowronska-Krawczyk D</submitter><funding>BLRD VA</funding><funding>NEI NIH HHS</funding><funding>NICHD NIH HHS</funding><funding>NIDDK NIH HHS</funding><funding>NIEHS NIH HHS</funding><funding>NHGRI NIH HHS</funding><funding>NCI NIH HHS</funding><funding>NIGMS NIH HHS</funding><pagination>931-40</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC4648709</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>59(6)</volume><pubmed_abstract>Glaucoma, a blinding neurodegenerative disease, whose risk factors include elevated intraocular pressure (IOP), age, and genetics, is characterized by accelerated and progressive retinal ganglion cell (RGC) death. Despite decades of research, the mechanism of RGC death in glaucoma is still unknown. Here, we demonstrate that the genetic effect of the SIX6 risk variant (rs33912345, His141Asn) is enhanced by another major POAG risk gene, p16INK4a (cyclin-dependent kinase inhibitor 2A, isoform INK4a). We further show that the upregulation of homozygous SIX6 risk alleles (CC) leads to an increase in p16INK4a expression, with subsequent cellular senescence, as evidenced in a mouse model of elevated IOP and in human POAG eyes. Our data indicate that SIX6 and/or IOP promotes POAG by directly increasing p16INK4a expression, leading to RGC senescence in adult human retinas. Our study provides important insights linking genetic susceptibility to the underlying mechanism of RGC death and provides a unified theory of glaucoma pathogenesis.</pubmed_abstract><journal>Molecular cell</journal><pubmed_title>P16INK4a Upregulation Mediated by SIX6 Defines Retinal Ganglion Cell Pathogenesis in Glaucoma.</pubmed_title><pmcid>PMC4648709</pmcid><funding_grant_id>R01 GM071872</funding_grant_id><funding_grant_id>R01 HD082567</funding_grant_id><funding_grant_id>R01 DK044838</funding_grant_id><funding_grant_id>P50 HD012303</funding_grant_id><funding_grant_id>T32 GM008666</funding_grant_id><funding_grant_id>R01 EY018660</funding_grant_id><funding_grant_id>P30EY022589</funding_grant_id><funding_grant_id>R01EY023704</funding_grant_id><funding_grant_id>P42 ES010337</funding_grant_id><funding_grant_id>I01 BX001898</funding_grant_id><funding_grant_id>P30 EY022589</funding_grant_id><funding_grant_id>U54 HD012303</funding_grant_id><funding_grant_id>R01 EY014448</funding_grant_id><funding_grant_id>R01HG008135</funding_grant_id><funding_grant_id>P30 DK063491</funding_grant_id><funding_grant_id>P30 CA023100</funding_grant_id><funding_grant_id>R01 EY014428</funding_grant_id><funding_grant_id>R01 HD072754</funding_grant_id><pubmed_authors>Flagg K</pubmed_authors><pubmed_authors>Weinreb RN</pubmed_authors><pubmed_authors>Mellon PL</pubmed_authors><pubmed_authors>Zhang K</pubmed_authors><pubmed_authors>Cao G</pubmed_authors><pubmed_authors>Krawczyk M</pubmed_authors><pubmed_authors>Zin C</pubmed_authors><pubmed_authors>Shi W</pubmed_authors><pubmed_authors>Zhang L</pubmed_authors><pubmed_authors>Krupa M</pubmed_authors><pubmed_authors>Liu Y</pubmed_authors><pubmed_authors>Zhao L</pubmed_authors><pubmed_authors>Ouyang H</pubmed_authors><pubmed_authors>Patel S</pubmed_authors><pubmed_authors>Zheng L</pubmed_authors><pubmed_authors>Jafari M</pubmed_authors><pubmed_authors>Wen C</pubmed_authors><pubmed_authors>Wang W</pubmed_authors><pubmed_authors>Li G</pubmed_authors><pubmed_authors>Rosenfeld MG</pubmed_authors><pubmed_authors>Zhuo Y</pubmed_authors><pubmed_authors>Li O</pubmed_authors><pubmed_authors>Skowronska-Krawczyk D</pubmed_authors><pubmed_authors>Ai M</pubmed_authors><pubmed_authors>Luo H</pubmed_authors><pubmed_authors>Zhong Z</pubmed_authors><pubmed_authors>Sun X</pubmed_authors><pubmed_authors>Chen D</pubmed_authors><pubmed_authors>Chung C</pubmed_authors><pubmed_authors>Zhu J</pubmed_authors><pubmed_authors>Yeh E</pubmed_authors><pubmed_authors>Luo J</pubmed_authors><pubmed_authors>Lin D</pubmed_authors><pubmed_authors>Shi C</pubmed_authors><pubmed_authors>Zhong S</pubmed_authors><pubmed_authors>Abagyan R</pubmed_authors><pubmed_authors>Gao W</pubmed_authors><pubmed_authors>Xu Y</pubmed_authors><view_count>58</view_count></additional><is_claimable>false</is_claimable><name>P16INK4a Upregulation Mediated by SIX6 Defines Retinal Ganglion Cell Pathogenesis in Glaucoma.</name><description>Glaucoma, a blinding neurodegenerative disease, whose risk factors include elevated intraocular pressure (IOP), age, and genetics, is characterized by accelerated and progressive retinal ganglion cell (RGC) death. Despite decades of research, the mechanism of RGC death in glaucoma is still unknown. Here, we demonstrate that the genetic effect of the SIX6 risk variant (rs33912345, His141Asn) is enhanced by another major POAG risk gene, p16INK4a (cyclin-dependent kinase inhibitor 2A, isoform INK4a). We further show that the upregulation of homozygous SIX6 risk alleles (CC) leads to an increase in p16INK4a expression, with subsequent cellular senescence, as evidenced in a mouse model of elevated IOP and in human POAG eyes. Our data indicate that SIX6 and/or IOP promotes POAG by directly increasing p16INK4a expression, leading to RGC senescence in adult human retinas. Our study provides important insights linking genetic susceptibility to the underlying mechanism of RGC death and provides a unified theory of glaucoma pathogenesis.</description><dates><release>2015-01-01T00:00:00Z</release><publication>2015 Sep</publication><modification>2024-11-09T14:20:19.53Z</modification><creation>2019-03-27T02:02:08Z</creation></dates><accession>S-EPMC4648709</accession><cross_references><pubmed>26365380</pubmed><doi>10.1016/j.molcel.2015.07.027</doi></cross_references></HashMap>